Showing results (21-30 of 152) with videos related to
Sort By:
Pageof 16
Antimicrobial Agents and Chemotherapy|July 24, 2013
Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885Kelly A Wong, Angela Worth, Ross Martin, et al.Liver International : Official Journal of the International Association for the Study of the Liver|April 6, 2026
Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in ELATIVECynthia Levy, Christopher L Bowlus, Eric Lawitz, et al.Contemporary Clinical Trials|April 7, 2023
A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - Study design and rationale of HM-TRIA-201 studyManal F Abdelmalek, Ayako Suzuki, Willian Sanchez, et al.Alimentary Pharmacology & Therapeutics|July 13, 2024
The effect of vitamin E and docosahexaenoic acid ethyl ester on Metabolic Dysfunction-Associated steatotic Liver Disease (MASLD)-A randomised, double-blind, placebo-controlled, parallel-group clinical trial (PUVENAFLD)Naim Alkhouri, Deanna McCarthy, Anne-Cécile V Bayne, et al.Journal of Hepatology|December 17, 2013
Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C)Zobair M Younossi, Maria Stepanova, Linda Henry, et al.Clinical Pharmacology and Therapeutics|January 24, 2025
Effect of Target-Mediated Disposition on Iptacopan Clinical Pharmacokinetics in Participants with Normal or Impaired Hepatic FunctionElise Burmeister Getz, Richard R Stein, Martin Fink, et al.Journal of Clinical Gastroenterology|March 14, 2020
Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver DiseaseAmandeep Singh, Falgun Gosai, Mohamed T Siddiqui, et al.Antiviral Research|January 25, 2011
Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapyEric Lawitz, Eliot Godofsky, Regine Rouzier, et al.World Journal of Hepatology|November 22, 2019
Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohortGeorge Khoudari, Amandeep Singh, Mazen Noureddin, et al.Liver International : Official Journal of the International Association for the Study of the Liver|January 30, 2018
Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertibZobair M Younossi, Maria Stepanova, Eric Lawitz, et al.Pageof 16